Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ba1675b350e489d4c88379e3b51440a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_604e07c32377cab416660b10fd8f494c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e71f4db94bfd1dc1765d731e90a3209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7653165f01c5f2df0011d29a3a55bda |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-686 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 |
filingDate |
2012-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4de8efbceef9bddec7643a1dd902cefd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a44ffba77b83553ed60de2f9457753b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c4a7d02782041c166249bab833b3e79 |
publicationDate |
2012-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2012125582-A1 |
titleOfInvention |
Biomarker for coronary artery disease |
abstract |
In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldheyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11168148-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3510046-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11361856-B2 |
priorityDate |
2011-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |